EUTOS Score for CML
The EUTOS score predicts likelihood of achieving complete cytogenetic response and progression‑free survival in CML using only basophil percentage and spleen size 1 [Level I evidence].
Indikationen
Used for newly diagnosed chronic‑phase CML to predict probability of achieving complete cytogenetic response and short‑term progression‑free survival on imatinib, guiding intensity of monitoring and identifying patients needing closer follow‑up. Based on basophils and spleen size; high‑risk patients had PPV 34% for failure to reach CCyR and 5‑year PFS 82% vs 90% in low‑risk patients (Blood 2011, 2060‑pt cohort 1 [Level I evidence]).
Hinweise & Vorsichtsmaßnahmen
Identifies higher risk of failing to reach complete cytogenetic response but has inconsistent survival prediction; original validation (n=2060) showed lower 5‑year PFS in high‑risk patients (82% vs 90%, P=.006) 1 [Level I evidence]. Multiple external cohorts show poor discrimination and no OS/PFS separation 2 [Level II evidence]. superseded by ELTS in 2025 ELN recommendations 3 [Level I evidence].